BILL WOULD EMPOWER FDA ON DRUG SAFETY

被引：0
|
作者：
不详
机构：
来源：
CHEMICAL & ENGINEERING NEWS | 2010年 / 88卷 / 32期
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [31] FDA alerts asthmatics to drug safety risk
    Clare Ellis
    Nature Reviews Drug Discovery, 2003, 2 : 765 - 765
  • [32] How the FDA Handles GI Drug Safety
    Lewis, James H.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (08): : 1264 - 1264
  • [33] FDA's role in drug safety.
    Graham, D.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2007, 165 (11) : S93 - S93
  • [34] BILL WOULD RETAIN PDP
    PHILLIPS, EH
    AVIATION WEEK & SPACE TECHNOLOGY, 1994, 140 (13): : 32 - 32
  • [35] Bill would expand NSF
    Brainard, Jeffrey
    SCIENCE, 2020, 368 (6494) : 921 - 921
  • [36] What would Bill think?
    Sparano, J. A.
    CANCER RESEARCH, 2020, 80 (04)
  • [37] Bill Inman - Drug safety physician and pharmacoepidemiologist - In memory
    Shakir, SAW
    DRUG SAFETY, 2006, 29 (03) : 187 - 188
  • [38] FDA drug labeling for pregnancy and lactation drug safety monitoring systems
    Greene, Michael F.
    SEMINARS IN PERINATOLOGY, 2015, 39 (07) : 520 - 523
  • [39] Post-market drug safety evidence sources: an analysis of FDA drug safety communications
    Ishiguro, Chieko
    Hall, Marni
    Neyarapally, George A.
    Dal Pan, Gerald
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (10) : 1134 - 1136
  • [40] Post-marketing drug safety sources: An evaluation of the FDA's drug safety communications
    Aldayel, Atheer
    Alghamdi, Maha
    Almutairi, Abdulaali
    Al-Harbi, Fawaz F.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 302 - 302
12345